Glenmark Pharmaceuticals has informed that it enclosed media release titled ‘Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure’.
The above information is a part of company’s filings submitted to BSE.